Members of the BoD and management team of Emplicure intend to exercise warrants of series TO1 corresponding to a value of app. SEK 1.2 million and enter into a lock-up undertaking
Members of the board of directors and management team of Emplicure AB (publ) ("Emplicure" or the "Company") intend to exercise held warrants of series TO1 and enter into a lock-up undertaking comprising all securities held by such persons at the time of the undertaking as well as the shares obtained through exercise of the warrants of series TO1. The number of warrants of series TO1 that the board of directors and the management team intend to exercise amounts to 588,227 warrants, corresponding to 6.1 percent of outstanding warrants of series TO1, corresponding to a subscription of 588,277 new shares to a value of approximately SEK 1.2 million. The lock-up commitments comprise 31.5 percent of the shares in the Company, calculated based on the number of shares in the Company at the time of this press release, and the commitments run up to and including 31 December 2022. The lock-up commitments also include the subscribed shares in connection with the exercise of warrants of series TO1. If all the warrants of series TO1 are exercised, the lock-up commitments will comprise 23.4 percent of the shares in the Company.
Summarized terms for warrants of series TO1:
Last day of exercise of TO1 for subscription of shares: 13 May 2022.
Subscription price: SEK 2.09 per share.
Volume: 9,600,000 warrants of series TO1. If all the warrants of series TO1 are exercised, the number of shares in the Company will increase with 9,600,00 shares, and the Company will receive approximately SEK 20.1million before issuing costs.
Last day for trading with warrants of series TO1: 11 May 2022.
Advisors Mangold Fondkommission AB is the financial advisor and issuing agent and Advokatfirman Lindahl KB is the legal advisor to Emplicure in connection with the exercise of the warrants.
For more information, please contact:
Torbjörn W. Larsson CEO Phone: +46 (0)70 747 65 99 Email: firstname.lastname@example.org
Emplicure is a pharmaceutical company developing new and innovative drugs by combining existing and approved active substances, and advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain, and with abuse deterrent formulations. The wholly owned subisidiary, Amplicon AB develops consumer products, with dry white oral nicotine pouches as the first product. Read more at www.emplicure.com